Interleukin-18: a biomarker with therapeutic potential in adult-onset Still’s disease

References

• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(6–14):6–14.
   PubMedGoogle Scholar
• Wang MY, Jia JC, Yang CD, et al. Pathogenesis, disease course, and prognosis of adult-onset Still’s disease: an update and review. Chin Med J (Engl). 2019;132(23):2856–2864.
   PubMedGoogle Scholar
• Hu QY, Zeng T, Sun CY, et al. Clinical features and current treatments of adult-onset Still’s disease: a multicenter survey of 517 patients in China. Clin Exp Rheumatol. 2019;37 Suppl 121(Suppl 121):52–57.
   PubMedGoogle Scholar
• Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset still’s disease: a single center case series and comparison with literature. Semin Arthritis Rheum. 2016;45(6):711–716.
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30(11):2422–2427.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31(11):2189–2198.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Terajima H, Harigai M, et al., Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheumatol. 2001;44(7):1716–1717.
   Google Scholar
• Chen DY, Chen YM, Lan JL, et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010;249(12):2305–2312.
   Google Scholar
• Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease: association with chronic articular disease. Rheumatol. 2001;40(12):1398–1404.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still’s disease. Ann Rheum Dis. 2004;63(10):1300–1306.
   PubMedGoogle Scholar
• Narula N, Narula T, Abril A. Seizing the clinical presentation in adult onset Still’s disease An extensive literature reviews. Autoimmun Rev. 2015;14(5):472–477.
   PubMedGoogle Scholar
• Chen PK, Chen DY, Bagatini MD. An update on the pathogenic role of macrophages in adult-onset Still’s disease and its implication in clinical manifestations and novel therapeutics. J Immunol Res. 2021;2021:8998358.
   PubMed Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–618.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Bindoli S, Galozzi P. Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances. Drugs. 2018;78(12):1187–1195.
   PubMedGoogle Scholar
• Castañeda S, Blanco R, González-Gay MA, Adult-onset Still’s. disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30(2):222–238.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, LeClercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52(6):1794.
   PubMedGoogle Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149–1159.
   PubMed Web of Science ®Google Scholar
• Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still’s disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302–308.
   PubMed Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13(3):R91.
   PubMed Web of Science ®Google Scholar
• Kedor C, Tomaras S, Baeumer D, et al. Update on the therapy of adult-onset Still’s disease with a focus on IL-1 inhibition: a systemic review. Ther Adv Musculoskel Dis. 2021; 13: 1–13.
   Google Scholar
• Puéchal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63(1):155–159.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol. 2018;28(5):849–857.
   PubMed Web of Science ®Google Scholar
• Kir S, Ozgen M, Zontul S. Adult-onset still’s disease and treatment results with tocilizumab. Int J Clin Pract. 2021;75(3):e13936.
   PubMedGoogle Scholar
• Tang KT, Hsieh CW, Chen HH, et al. The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clin Rheumatol. 2022;41(2):557–566.
   PubMedGoogle Scholar
• Gabay C, Fautrel B, Rech J, et al., Open-label, multicentre, dose-escalating, phase II clinical trial on the safety and efficacy of tadekining alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77(6):840–847.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still’s disease: a systemic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089–1097.
   PubMed Web of Science ®Google Scholar
• Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784–790.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, et al., Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995;378(6552):88–91.
   PubMed Web of Science ®Google Scholar
• Okamura H, Nagata K, Komatsu T, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun. 1995;63(10):3966–3972.
   PubMedGoogle Scholar
• Boraschi D, Dinarello CA. IL-18 in autoimmunity: review. Eur Cytokine Netw. 2006;17(4):224–252.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27(1):98–114.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Nakanishi K. Immunotherapeutic applications of IL-18. Immunotherapy. 2012;4(12):1883–1894.
   PubMed Web of Science ®Google Scholar
• Novick D, Kim S, Kaplanski G, et al. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25(6):439–448.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Kaplanski G. Indeed, IL-18 is more than an inducer of IFNγ. J Leukoc Biol. 2018;104(2):237–238.
   PubMedGoogle Scholar
• Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996;26(7):1647–1651.
   PubMedGoogle Scholar
• Kim ML, Chae JJ, Park YH, et al. Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med. 2015;212(6):927–938.
   PubMed Web of Science ®Google Scholar
• Dolasia K, Bisht MK, Pradhan G, et al. TLRs/NLRs: shaping the landscape of host immunity. Int Rev Immunol. 2018;37(1):3–19.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH, Kim HA. The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still’s disease. Expert Rev Mol Diagn. 2019;19(6):459–468.
   PubMed Web of Science ®Google Scholar
• Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103–107.
   PubMed Web of Science ®Google Scholar
• Martinon F, Gaide O, Petrilli V, et al. NALP inflammasome: a central role in innate immunity. Semin Immunopathol. 2007;29(3):213–229.
   PubMed Web of Science ®Google Scholar
• Hsieh CW, Chen YM, Lin CC, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J Rheumatol. 2017;44(8):1142–1150.
   PubMed Web of Science ®Google Scholar
• Heilig R, Dick MS, Sborgi L, et al. The gasdermin-D pore acts a conduit for IL-1β secretion in mice. Eur J Immunol. 2018;48(4):584–592.
   PubMed Web of Science ®Google Scholar
• Nagai H, Kirino Y, Nakano H, et al. Elevated serum gasdermin D N-terminal implicates monocyte and macrophage pyroptosis in adult-onset Still’s disease. Rheumatology (Oxford). 2021;60(8):3888–3895.
   PubMedGoogle Scholar
• Platnich JM, Muruve DA. NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways. Arch Biochem Biophys. 2019;670:4–14.
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
   PubMed Web of Science ®Google Scholar
• Wouters JMGW, van der Veen J, van de Putte LBA, et al. Adult Still’s disease and viral infection. Ann Rheum Dis. 1988;47(9):764–767.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Quakil H, Debin ML, et al. Adult Still’s disease associated with acute human parvovirus B19 infection. Lancet. 1993;341(8855):1280–1281.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lan JL, et al. Significant association of past parvovirus B19 infection with cytopenia and arthritis in patients with adult-onset Still’s disease. Clin Chim Acta. 2012;413(9–10):855–860.
   PubMedGoogle Scholar
• Schifter T, Lewinski UH. Adult onset Still’s disease associated with Epstein-Barr virus infection in a 66-year-old woman. Scand J Rheumatol. 1998;27(6):458–460.
   PubMedGoogle Scholar
• Yoshioka K, Fujimoto S, Oba H, et al. Onset of adult-onset-Still’s disease following influenza vaccination. Mod Rheumatol. 2011;21(4):432–435.
   PubMed Web of Science ®Google Scholar
• Jia J, Shi H, Liu M, et al. Cytomegalovirus infection may trigger adult-onset Still’s disease onset or relapse. Front Immunol. 2019;10:898.
   PubMedGoogle Scholar
• Pichon M, Claire LP, Genet P, et al. Adult-onset Still’s disease in a patient with human immunodeficiency virus infection: pathophysiological link? Rheumatology (Oxford). 2020;59(11):e99–e101.
   PubMedGoogle Scholar
• Agnihotri A, Ruff A, Gotterer L, et al. Adult onset Still’s disease associated with mycoplasma pneumoniae infection and hemophagocytic lymphohistiocytosis. Case Rep Med. 2016;2016:2071815.
   PubMedGoogle Scholar
• Bamidis AD, Koehler P, Di Cristanziano V, et al. First manifestation of adult-onset Still’s disease after COVID-19. Lancet Rheumatol. 2021;3(5):e319–e21.
   PubMedGoogle Scholar
• Chen DY, Chen YM, Chen HH, et al. Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still’s disease. Mol Med Rep. 2018;17(2):3364–3371.
   PubMedGoogle Scholar
• Fujita Y, Yago T, Asano T, et al. Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still’s disease. PLoS One. 2021;16(8):e0255493.
   PubMedGoogle Scholar
• Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 2012;488(7413):670–674.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH, Sohn S, et al. Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin raash. Clin Rheumatol. 2016;35(8):1937–1942.
   PubMedGoogle Scholar
• Chen PK, Lan JL, Li JP, et al. Elevated plasma galectin-3 levels and their correlation with disease activity in adult-onset Still’s disease. Clin Rheumatol. 2020;39(6):1945–1952.
   PubMedGoogle Scholar
• Hu Q, Shi H, Zeng T, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther. 2019;21(1):9.
   PubMed Web of Science ®Google Scholar
• Ahn MH, Han JH, Chwae YJ, et al. Neutrophil extracellular traps may contribute to the pathogenesis in adult-onset still disease. J Rheumatol. 2019;46:1560–1569.
   PubMedGoogle Scholar
• Jung KH, Kim JJ, Lee JS, et al. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol. 2014;43(2):162–169.
   PubMed Web of Science ®Google Scholar
• Kudela H, Drynda S, Lux A, et al. Comparative study of interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol. 2019;3(1):4.
   PubMedGoogle Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–1376.
   PubMed Web of Science ®Google Scholar
• Nolan KF, Greaves DR, Waldmann H. The human interleukin 18 gene maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. Genomics. 1998;51(1):161–163.
   PubMedGoogle Scholar
• Kalina U, Ballas K, Koyama N, et al. Genomic organization and regulation of the human interleukin-18 gene. Scand J Immunol. 2000;52(6):52530.
   Google Scholar
• Takeuchi M, Okura T, Mori T, et al. Intracellular production of interleukin-18 in human epithelial-like cell lines is enhanced by hyperosmotic stress in vitro. Cell Tissue Res. 1999;297(3):467–473.
   PubMedGoogle Scholar
• Sugiura T, Kawaguchi Y, Harigai M, et al. Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun. 2002;3(7):394–399.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Maeno N, Kawaguchi Y, et al. A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Thera. 2006;8(3):R60.
   PubMed Web of Science ®Google Scholar
• Giedraitis V, He B, Huang WX, et al. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112(1–2):146–152.
   PubMed Web of Science ®Google Scholar
• Woo JH, Seong SS, Yoo DH. Association of interleukin 18 polymorphisms with adult onset Still’s disease in Korea. J Rheumatol. 2007;34(7):1637–1639.
   PubMedGoogle Scholar
• Chen DY, Chen YM, Chen HH, et al. Functional association of IL-18 gene –607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset still’s disease. J Rheumatol. 2009;36(10):2284–2289.
   PubMedGoogle Scholar
• Hung WT, Chen YM, Hung SI, et al. CARD8 single-nucleotide polymorphism rs11672725 identified as a potential genetic variant for adult-onset still’s disease. Life (Basel). 2021;11(5):382.
   PubMedGoogle Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369–2376.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–430.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Alessandri C, et al. IL-18 serum levels in adult onset Still’s disease: a marker of disease activity. Int J Inflam. 2012;2012:156890.
   PubMedGoogle Scholar
• Girard C, Rech J, Brown M, et al., Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55(12):2237–2247.
   PubMed Web of Science ®Google Scholar
• Priori R, Colafrancesco S, Alessandri C, et al. Interleukin-18: a biomarker for differential diagnosis between adult-onset Still’s disease and sepsis. J Rheumatol. 2014;41(6):1118–1123.
   PubMedGoogle Scholar
• Kim HA, An JM, Nam JY, et al. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin-18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2012;39(7):1399–1406.
   PubMedGoogle Scholar
• Koga T, Sumiyoshi R, Furukawa K, et al. Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still’s disease from sepsis. Arthritis Res Ther. 2020;22(1):108.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yang T, Zhang H, et al. Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still’s disease: a prospective cohort study. Cytokine. 2021;46:155642.
   Google Scholar
• Colafrancesco S, Alessandri C, Conti F, et al. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020;19(7):102573.
   PubMed Web of Science ®Google Scholar
• Meng J, Ma Y, Jia J, et al. Cytokine storm in coronavirus disease 2019 and adult-onset Still’s disease: similarities and differencies. Front Immunol. 2021;11:603389.
   PubMedGoogle Scholar
• Chen PK, Lan JL, Huang PH, et al. Interleukin-18 is a potential biomarker to discriminate active adult-onset Still’s disease from COVID-19. Front Immunol. 2021;12:719544.
   PubMedGoogle Scholar
• Ravelli A, Minoia F, Davì S, et al. The 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organization collaborative initiative. Arthritis Rheumatol. 2016;68(3):566–576.
   PubMed Web of Science ®Google Scholar
• Crayne CB, Albeituni S, Nichols KE, et al. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult-onset Still’s disease: analysis of survival rates and predictive factors in the gruppo italiano di ricerca in rheumatologia clinica e sperimentale cohort. J Rheumatol. 2018;45(6):864.
   PubMed Web of Science ®Google Scholar
• Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2019;58(1):517.
   Google Scholar
• Maakaroun NR, Moanna A, Jacob JT, et al. Viral infections associated with hemophagocytic syndrome. Rev Med Virol. 2010;20(2):93–105.
   PubMed Web of Science ®Google Scholar
• Tsuchida Y, Sumitomo S, Shoda H, et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2017;7(3):556–557.
   Google Scholar
• Wang R, Li T, Ye S, et al., Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis. Clin Rheumatol. 2020;39(8):2379–2386.
   PubMedGoogle Scholar
• Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37(5):967–973.
   PubMed Web of Science ®Google Scholar
• Krei JM, Møller HJ, Larsen JB. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome – a systematic review. Clin Exp Immunol. 2021;203(2):174–182.
   PubMedGoogle Scholar
• Weiss ES, Girard-Guyonvarc’h C, Holzinger D, et al., Interleukin-18 diagnostically distinguished and pathologically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442–1455.
   PubMed Web of Science ®Google Scholar
• Avau A, Mitera T, Put S, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation of interferon-γ. Arthritis Rheumatol Hoboken NJUSA. 2014;66(5):1340–1351.
   PubMedGoogle Scholar
• Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264–2267.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(48):124–131.
   PubMedGoogle Scholar
• Girard-Guyonvarc’h C, Palomo J, Martin P, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood. 2018;131(13):1430–1441.
   PubMed Web of Science ®Google Scholar
• Shiga T, Nozaki Y, Tomita D, et al. Usefulness of IL-18 as a diagnostic biomarker to differentiate adult-onset Still’s disease with/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults. Front Immunol. 2021;12:750114.
   PubMedGoogle Scholar
• Ohta A, Yamaguchi M, Kaneoka H, et al. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol. 1987;14(6):1139–1146.
   PubMedGoogle Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–99.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review of adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Cutaneous manifestations associated with adult-onset Still’s disease: important diagnostic values. Rheumatol Int. 2012;32(8):2233–2237.
   PubMed Web of Science ®Google Scholar
• Maeda-Aoyama N, Hamada-Ode K, Taniguchi Y, et al. Dyskeratotic cells in persistent pruritic skin lesions as a prognostic factor in adult-onset Still disease. Medicine (Baltimore). 2020;99(6):e19051.
   PubMedGoogle Scholar
• Conigliaro P, Priori P, Bombardieri M, et al. Lymph node IL-18 expression in adult-onset Still’s disease. Ann Rheum Dis. 2009;68(3):442–443.
   PubMedGoogle Scholar
• Maeno N, Takei S, Imanaka H, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004;50(6):1935–1938.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Adachi K, Seki E, et al. Cytokine-induced inflammatory liver injuries. Curr Mol Med. 2003;3(6):545–559.
   PubMedGoogle Scholar
• Priori R, Barone F, Alessandri C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50(4):776–780.
   PubMed Web of Science ®Google Scholar
• Ogata A, Kitano M, Yamanaka J, et al. Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult onset Still’s disease. J Rheumatol. 2003;30(5):1093–1096.
   PubMedGoogle Scholar
• Chen DY, Lan JL, Lin FJ, et al. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active untreated adult onset Still’s disease. Arthritis & Rheumatism. 2005;53(3):320–327.
   PubMedGoogle Scholar
• Cush JJ, Medsger TA, Christy WC, et al. Adult-onset Still’s disease: clinical course and outcome. Arthritis Rheum. 1987;30(2):186–194.
   PubMedGoogle Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheumatol. 2010;62(8):2530–2535.
   PubMedGoogle Scholar
• Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642–646.
   PubMed Web of Science ®Google Scholar
• Chen PK, Hsieh SL, Lan JL, et al. Elevated expression of C-type lectin domain family 5-member A (CLE5A) and its relation to inflammatory parameters and disease course in adult-onset Still’s disease. J Immunol Res. 2020;2020:9473497.
   PubMedGoogle Scholar
• Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135(5):3172–3177.
   PubMed Web of Science ®Google Scholar
• Nam SW, Kang SM, Lee JH, et al. Differential features of interleukin-37 and interleukin-18 as disease activity markers of adult-onset Still’s disease. J Clin Med. 2021;10(5):910.
   PubMedGoogle Scholar
• Chen ST, Lin YL, Huang MT, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature. 2008;453(7195):672–678.
   PubMed Web of Science ®Google Scholar
• Cheung R, Shen F, Phillips JH, et al. Activation of MDL-1 (CLE5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest. 2011;121(11):4446–4461.
   PubMedGoogle Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369–2376.
   PubMed Web of Science ®Google Scholar
• Yoo DH. Treatment of adult-onset still’s disease: up to date. Expert Rev Clin Immunol. 2017;13(9):849–866.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.
   PubMed Web of Science ®Google Scholar
• Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
   PubMed Web of Science ®Google Scholar
• Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21(1):53.
   PubMedGoogle Scholar
• Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281(1):138–153.
   PubMed Web of Science ®Google Scholar
• Kim SH, Eisenstein M, Reznikov L, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000;97(3):1190–1195.
   PubMedGoogle Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.
   PubMed Web of Science ®Google Scholar
• Aizawa Y, Akita K, Taniai M, et al. Cloning and expression of interleukin-18 binding protein. FEBS Lett. 1999;445(2–3):338–342.
   PubMedGoogle Scholar
• Novick D, Kim SH, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999;10(1):127–136.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Yamamura M, Taniai M, et al., Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44(3):550–560.
   PubMedGoogle Scholar
• Harel M, Fauteux-Daniel S, Girard-Guyonvarc’h C, et al. Balance between interleukin-18 and interleukin-18 binding protein in auto-inflammatory diseases. Cytokine. 2022;150:155781.
   PubMedGoogle Scholar
• Harel M, Girard-Guyonvarc’h C, Rodriguez E. Production of IL-18 binding protein by radiosensitive and radioresistant cells in CpG-induced macrophage activation syndrome. J Immunol. 2020;205(4):1167–1175.
   PubMedGoogle Scholar
• Put K, Avau A, Brisse E, et al. Cytokines in systemic juvenile idiopathic arthritis and haemaphagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma. Rheumatology (Oxford). 2015;54(8):1507–1517.
   PubMed Web of Science ®Google Scholar
• Yasin S, Solomon K, Canna SW, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):442–445.
   PubMed Web of Science ®Google Scholar
• Chen O, Shan N, Zhu X, et al. The imbalance of IL-18/IL-18BP in patients with systemic juvenile idiopathic arthritis. Acta Biochim Biophys Sin. 2013;45(4):339–341.
   Google Scholar
• Liao TL, Chen YM, Hsieh CW, et al. Upregulation of circulating microRNA-134 in adult-onset Still’s disease and its use as potential biomarker. Sci Rep. 2017;7(1):4214.
   PubMedGoogle Scholar
• Pietrzak A, Lecewicz-Torun B, Chodorowska G, et al. Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Derm Venerol. 2003;83(4):262–265.
   PubMed Web of Science ®Google Scholar
• Shimoura N, Nagai H, Fujiwara S, et al. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch Dermatol Res. 2017;309(4):315–321.
   PubMed Web of Science ®Google Scholar
• Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet. 2006;31(2):109–116.
   PubMed Web of Science ®Google Scholar
• Tsutsumi N, Kimura T, Arita K, et al. The structural basis for receptor recognition of human interleukin-18. Nat Commun. 2014;5(1):5340.
   PubMed Web of Science ®Google Scholar
• Wei H, Wang D, Qian Y, et al. Structural basis for the specific recognition of IL-18 by its alpha receptor. FEBS Lett. 2014;588(21):3838–3843.
   PubMedGoogle Scholar
• Girard-Guyonvarc’h C, Harel M, Gabay C. The role of interleukin 18/interleukin 18-binding protein in adult-onset Still’s disease and systemic juvenile idiopathic arthritis. J Clin Med. 2022;11(2):430.
   PubMedGoogle Scholar
• Kiltz U, Kiefer D, Braun J, et al. Prolonged treatment with tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis. 2020;79(1):e10.
   PubMed Web of Science ®Google Scholar
• Nariai Y, Kamino H, Obayashi E, et al. Generation and characterization of antagonistic anti-human interleukin (IL)- 18 monoclonal antibodies with high affinity: two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18. Arch Biochem Biophys. 2019;663:71–82.
   PubMedGoogle Scholar
• Liao TL, Chen YM, Tang KT, et al. MicroRNA-223 inhibits IL-18-mediated neutrophil extracellular trap through regulating calcium influx in adult-onset Still’s disease. Sci Rep. 2021;11(1):15676.
   PubMedGoogle Scholar
• Maranini B, Ciancio G, Govoni M. Adult-onset disease: novel biomarkers of specific subsets, disease activity, and relapsing forms. Int J Mol Sci. 2021;22(24):13320.
   PubMedGoogle Scholar
• Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still’s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858–874.
   PubMedGoogle Scholar
• Silva JR, Brito I. Systemic juvenile idiopathic arthritis versus adult-onset Still’s disease: the pertinence of changing the current classification criteria. Acta Rheumatol Port. 2020;45:150–151.
   PubMedGoogle Scholar
• Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol. 2015;11(6):749–761.
   PubMed Web of Science ®Google Scholar